Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders

E-ISSN： 2212-2710|3|2|84-95

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.3, Iss.2, 2009-06, pp. : 84-95

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CTLA-4Ig: Uses and Future Directions

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 3, Iss. 2, 2009-06 ,pp. : 132-142

Bentham Science Publishers

Access to resources Recommend Favorite

The Therapeutic Potential of Melatonin in Neurological Disorders

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 3, Iss. 1, 2009-01 ,pp. : 60-64

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 2, 2007-06 ,pp. : 157-161

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 3, 2007-11 ,pp. : 193-201

Bentham Science Publishers

Access to resources Recommend Favorite

Chemokines as Novel Therapeutic Targets in Autoimmune Thyroiditis

Recent Patents on DNA & Gene Sequences, Vol. 4, Iss. 1, 2010-01 ,pp. : 52-57

Bentham Science Publishers

Access to resources Recommend Favorite